REGENERON PHARMACEUTICALS, INC. — Form 10-Q
Filed October 30, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 73/100
What the filing says
On 1 October 2026, Regeneron and Sanofi amended their license-collaboration agreement to add four new licensed products: REGN20423 (IL-13 antibody), REGN23149 (IL-4Rα antibody), REGN23262 (IL-4 antibody), and REGN35937/REGN36405 (IL-13/IL-4 bi-specific molecules). Sanofi pays Regeneron $1B upfront immediately and up to $7B in milestone payments ($1B at first patient dosed in registrational trial, $1.5B at first approval, $1.5B at $[*] net sales threshold, $1B at second approval, $1B each at two higher sales thresholds). Development costs 50/50 co-funded effective immediately; profit split 50/50 in rest-of-world; Regeneron leads development globally, Sanofi leads commercialization in ROW; Regeneron has co-promotion rights in specified countries. Manufacturing technology transfer costs split 50/50.
Why this rating
Material $1B+$7B deal (~1.5% of $54.8B market cap) expands profitable franchise with defined economics; adds 4 assets in high-value allergy/inflammation space; royalty-free profit-sharing structure benefits Regeneron long-term.
Price action (we called it positive)
before filing · preread $879.51 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.